Home Newsfeeds Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $12

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $12

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $16 to $12.

byBenzinga Newsdesk

March 16, 2023

1 minute read

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $16 to $12.

Analysts Bullish On Cannabis Co. TerrAscend Post-Earnings: Raised Targets And Upgraded Ratings

By Javier Hasse

November 10, 3:30 PM

In the wake of TerrAscend Corp. (OTC: TSNDF)'s impressive third-quarter earnings, several analysts have revised their ratings and price targets, signaling renewed optimism for the cannabis company's prospects.

TSNDF

Green Thumb Industries’ Annual General Meeting, Elects Directors And Approves Executive Compensation

By Rolando García

June 14, 1:25 PM

Read about the key outcomes of Green Thumb Industries' 2024 AGM, including director elections and approval of executive compensation.

GTBIF

TREES To Acquire Green Man Cannabis Dispensary

By Vuk Zdinjak

November 3, 10:48 AM

TREES Corporation (OTCQB: CANN) signed a definitive agreement to acquire GMC LLC d/b/a Green Man Cannabis Dispensary, located in Denver. This purchase continues the rapid and targeted expansion of TREES’ dispensary footprint to 8 stores in 2 states.

CANN